Health Catalyst (NASDAQ:HCAT) Stock Price Down 2.9% – Should You Sell?

Health Catalyst, Inc. (NASDAQ:HCAT)’s share price fell 2.9% during trading on Friday. The company traded as low as $1.69 and last traded at $1.69. Approximately 159,996 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 383,153 shares. The stock had previously closed at $1.74.

Analysts Set New Price Targets

Several equities analysts recently weighed in on HCAT shares. Wells Fargo & Company cut their price objective on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating for the company in a research report on Thursday, August 13th. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $1.80 target price (down from $3.00) on shares of Health Catalyst in a report on Thursday, August 20th. Weiss Ratings raised Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. Finally, Citigroup dropped their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Two investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $2.15.

Health Catalyst Trading Down 2.9%

The company has a debt-to-equity ratio of 1.51, a quick ratio of 2.70 and a current ratio of 2.70. The company’s 50 day moving average is $1.72 and its 200 day moving average is $1.70. The stock has a market capitalization of $127.19 million, a price-to-earnings ratio of -0.46 and a beta of 1.54.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. The company had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. On average, research analysts forecast that Health Catalyst, Inc. will post -0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Simeon Kohl bought 59,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average cost of $1.79 per share, with a total value of $105,610.00. Following the completion of the transaction, the chief executive officer directly owned 2,856,385 shares in the company, valued at $5,112,929.15. This represents a 2.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.40% of the stock is currently owned by company insiders.

Institutional Trading of Health Catalyst

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Health Catalyst during the 2nd quarter worth approximately $3,654,000. Hsbc Holdings PLC increased its position in shares of Health Catalyst by 313.3% during the second quarter. Hsbc Holdings PLC now owns 408,634 shares of the company’s stock valued at $809,000 after purchasing an additional 309,766 shares during the period. Palogic Value Management L.P. bought a new stake in shares of Health Catalyst during the second quarter valued at approximately $9,796,000. Squarepoint Ops LLC increased its position in shares of Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company’s stock valued at $796,000 after purchasing an additional 369,772 shares during the period. Finally, AXQ Capital LP acquired a new position in shares of Health Catalyst in the second quarter valued at $38,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.

The company’s offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.